Equities

Chiome Bioscience Inc

4583:TYO

Chiome Bioscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)123.00
  • Today's Change-2.00 / -1.60%
  • Shares traded125.00k
  • 1 Year change-37.24%
  • Beta1.0804
Data delayed at least 20 minutes, as of May 10 2024 05:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.

  • Revenue in JPY (TTM)682.46m
  • Net income in JPY-1.22bn
  • Incorporated2005
  • Employees51.00
  • Location
    Chiome Bioscience Inc12F,Smtm Fdsn Nshi-shnjk Bldg. No.63-12-1, Hon-machiSHIBUYA-KU 151-0071JapanJPN
  • Phone+81 363833561
  • Websitehttps://www.chiome.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kidswell Bio Corp2.62bn-1.21bn5.51bn41.00--3.73--2.11-37.72-37.7277.5637.570.55831.264.0063,807,830.00-25.82-58.77-36.65-77.4450.3059.87-46.25-139.311.86-21.980.6118--76.9221.24-22.83------
KAINOS Laboratories, Inc.4.98bn647.70m5.57bn144.007.890.83327.221.12154.88154.881,192.401,466.620.6052.893.1334,615,160.007.866.6610.259.0751.4151.5212.999.892.53--0.113317.016.692.3310.9015.37-46.2314.87
Cyfuse Biomedical KK61.11m-589.21m5.68bn21.00--1.77--92.87-75.45-75.457.82405.800.01350.54073.982,910,095.00-13.05---15.34--61.76---964.15--5.92-71.550.2218---83.68---24.32------
Delta-Fly Pharma Inc0.00-1.26bn6.00bn11.00--3.55-----187.93-187.930.00205.250.00----0.00-92.45-53.35-103.56-55.60-------769.75---391.170.00---100.00---37.37------
Noile-Immune Biotech Inc316.82m-1.13bn6.67bn28.00--1.17--21.05-26.14-26.147.32131.420.06080.1818--11,314,930.00-21.69---22.60--99.29---356.68--66.04--0.00---49.37---192.28------
NIPPON CHEMIPHAR CO., LTD.30.61bn-241.00m6.82bn872.00--0.30825.710.2229-66.77-66.778,482.425,194.100.60632.092.6535,106,650.00-0.47931.20-0.67771.7425.0934.53-0.79051.771.61--0.485238.20-2.91-2.23-51.57-21.81-13.06-12.94
CellSeed Inc190.13m-846.53m7.05bn35.00--3.18--37.09-29.28-29.286.6168.810.09481.624.905,432,400.00-42.22-49.69-45.69-54.5556.3663.66-445.23-428.6218.66-601.010.0653--50.39-28.62-11.43--80.73--
Chiome Bioscience Inc682.46m-1.22bn7.08bn51.00--5.73--10.38-24.67-24.6713.7722.000.34414.196.8813,381,650.00-61.51-50.50-79.81-57.3858.4157.53-178.77-224.742.90-513.930.2009--8.1926.241.84------
DNA Chip Research Inc431.66m-284.71m7.26bn36.00--14.41--16.82-45.19-45.1968.7774.440.67288.525.3111,990,420.00-44.38-21.72-55.27-24.436.0217.16-65.96-50.031.90--0.00---23.46-2.03-170.31--33.58--
Symbio Pharmaceuticals Ltd4.64bn-2.74bn7.48bn109.00--1.04--1.61-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43-------44.157.82-266.45--42.39--
Carna Biosciences, Inc.1.63bn-1.15bn7.56bn67.00--1.95--4.65-69.84-69.8496.78226.160.37741.363.3524,267,000.00-26.76-14.45-29.55-16.9589.2290.59-70.91-35.4210.78-312.970.0451--17.2416.5914.57---27.69--
K Pharma Inc1.00bn260.33m7.58bn15.0028.762.44--7.5822.7122.7186.17267.55------66,666,670.00--------91.00--26.03--18.48--0.00------166.34------
Wakamoto Pharmaceutical Co Ltd7.98bn-177.67m8.12bn292.00--0.691134.901.02-5.12-5.12229.89337.150.5252.082.8827,324,600.00-1.17-2.58-1.34-3.0046.9853.08-2.23-4.333.45--0.0085--3.31-4.50-42.041.88-17.490.00
Kohjin Bio Co Ltd-100.00bn-100.00bn8.22bn157.00--2.58----------634.95------------------------1.15--0.4102--20.16--41.20------
CanBas Co Ltd (Parent)0.00-1.07bn8.42bn12.00--2.67-----64.96-64.960.00174.810.00----0.00-40.62-65.86-42.95-79.11-------1,094.10----0.00-------45.41------
Tsubota Laboratory Inc246.60m-1.07bn9.03bn10.00--8.57--36.61-42.31-42.319.9441.170.10232.2029.1624,660,200.00-44.25---64.34---182.07---432.63--1.92-417.040.1046--48.96---41.18------
Data as of May 10 2024. Currency figures normalised to Chiome Bioscience Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.43%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 04 Apr 2024236.70k0.43%
Data from 19 Apr 2024 - 19 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.